Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.91 +0.04 (+4.48%)
As of 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VRAX vs. SNPX, PHXM, TLPH, CLDI, ADXN, GOVX, GLYC, APRE, XFOR, and CYCN

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Calidi Biotherapeutics (CLDI), Addex Therapeutics (ADXN), GeoVax Labs (GOVX), GlycoMimetics (GLYC), Aprea Therapeutics (APRE), X4 Pharmaceuticals (XFOR), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Virax Biolabs Group (NASDAQ:VRAX) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Virax Biolabs Group has higher revenue and earnings than Synaptogenix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K394.51-$6.06MN/AN/A
SynaptogenixN/AN/A-$12.77M-$10.08-0.96

Virax Biolabs Group currently has a consensus target price of $3.00, suggesting a potential upside of 230.03%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Synaptogenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Synaptogenix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Virax Biolabs Group's return on equity of 0.00% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Synaptogenix N/A -115.28%-58.31%

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.89 beat Synaptogenix's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company Overall Sentiment
Virax Biolabs Group Very Positive
Synaptogenix Very Positive

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Summary

Virax Biolabs Group beats Synaptogenix on 10 of the 11 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.95M$2.92B$5.56B$9.30B
Dividend YieldN/A2.43%4.23%4.03%
P/E RatioN/A20.3828.6319.67
Price / Sales394.51304.58439.23185.66
Price / CashN/A43.1536.0257.93
Price / Book0.727.738.185.64
Net Income-$6.06M-$55.11M$3.23B$257.73M
7 Day Performance-1.58%0.65%-0.20%0.21%
1 Month Performance4.45%8.17%5.43%8.47%
1 Year Performance-28.98%-2.67%26.39%13.93%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
3.082 of 5 stars
$0.91
+4.5%
$3.00
+230.0%
-23.0%$3.95M$10K0.005Positive News
SNPX
Synaptogenix
0.3117 of 5 stars
$7.63
-10.2%
$14.00
+83.5%
+130.2%$10.61MN/A-0.764Positive News
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
TLPH
Talphera
2.3684 of 5 stars
$0.50
+8.6%
$5.00
+894.8%
-52.5%$10.31M$27K-1.1219
CLDI
Calidi Biotherapeutics
0.566 of 5 stars
$0.32
+33.6%
N/A-67.1%$10.21MN/A0.0038Gap Up
High Trading Volume
ADXN
Addex Therapeutics
2.5147 of 5 stars
$9.52
+1.5%
$30.00
+215.1%
+8.5%$10.09M$460K-28.0030Positive News
Gap Down
GOVX
GeoVax Labs
2.2181 of 5 stars
$0.63
+25.4%
$11.10
+1,661.9%
-75.4%$10.04M$3.95M-0.1710Analyst Upgrade
High Trading Volume
GLYC
GlycoMimetics
0.5088 of 5 stars
$0.16
-6.6%
N/A-99.5%$10.00M$10K-0.3450High Trading Volume
APRE
Aprea Therapeutics
2.8943 of 5 stars
$1.80
+4.0%
$15.50
+761.1%
-58.4%$9.95M$1.50M-0.767Gap Up
XFOR
X4 Pharmaceuticals
4.925 of 5 stars
$1.69
flat
$72.33
+4,192.8%
-93.1%$9.76M$2.56M0.7980Positive News
Gap Up
High Trading Volume
CYCN
Cyclerion Therapeutics
2.5311 of 5 stars
$3.01
-2.6%
N/A+8.9%$9.66M$2M-2.5930News Coverage

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners